AR and neoplasm: Tumour growth inhibition has been reported with enzalutamide in an EOC xenograft model.21 There is a phase II trial of enzalutamide in patients with AR+ (5% cut off) EOC who have had a maximum of three prior lines of cytotoxic therapy.